SUPRIYAPharmaceuticals
Supriya Lifescience Ltd — Profit & Loss Statement
₹561.90
-1.58%
Supriya Lifescience Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.77 Cr | -0.10 Cr | — |
| Tax Rate For Calcs | 0.24 | 0.28 | 0.28 | 0.27 | — |
| Normalized EBITDA | 270.59 Cr | 183.61 Cr | 139.78 Cr | 220.54 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -2.80 Cr | -0.37 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -2.80 Cr | -0.37 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Reconciled Depreciation | 20.44 Cr | 15.81 Cr | 11.81 Cr | 10.12 Cr | — |
| Reconciled Cost Of Revenue | 211.18 Cr | 221.74 Cr | 230.55 Cr | 229.89 Cr | — |
| EBITDA | 270.59 Cr | 183.61 Cr | 136.98 Cr | 220.17 Cr | — |
| EBIT | 250.15 Cr | 167.80 Cr | 125.17 Cr | 210.06 Cr | — |
| Net Interest Income | -1.67 Cr | -2.11 Cr | 6.43 Cr | 3.22 Cr | — |
| Interest Expense | 1.67 Cr | 2.11 Cr | 1.68 Cr | 2.81 Cr | — |
| Normalized Income | 187.96 Cr | 119.11 Cr | 91.88 Cr | 152.08 Cr | — |
| Net Income From Continuing And Discontinued Operation | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Total Expenses | 456.13 Cr | 413.18 Cr | 335.70 Cr | 317.22 Cr | — |
| Diluted Average Shares | 8.05 Cr | 8.05 Cr | 8.05 Cr | 8.05 Cr | — |
| Basic Average Shares | 8.05 Cr | 8.05 Cr | 8.05 Cr | 8.05 Cr | — |
| Diluted EPS | 23.35 | 14.80 | 11.16 | 18.86 | — |
| Basic EPS | 23.35 | 14.80 | 11.16 | 18.86 | — |
| Diluted NI Availto Com Stockholders | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Net Income Common Stockholders | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Net Income Including Noncontrolling Interests | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 187.96 Cr | 119.11 Cr | 89.86 Cr | 151.81 Cr | — |
| Tax Provision | 60.52 Cr | 46.58 Cr | 33.63 Cr | 55.44 Cr | — |
| Pretax Income | 248.48 Cr | 165.69 Cr | 123.49 Cr | 207.25 Cr | — |
| Other Non Operating Income Expenses | 9.81 Cr | 10.63 Cr | 9.49 Cr | 0.01 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -2.80 Cr | -0.37 Cr | — |
| Net Non Operating Interest Income Expense | -1.67 Cr | -2.11 Cr | 6.43 Cr | 3.22 Cr | — |
| Interest Expense Non Operating | 1.67 Cr | 2.11 Cr | 1.68 Cr | 2.81 Cr | — |
| Operating Income | 240.35 Cr | 157.16 Cr | 115.32 Cr | 202.16 Cr | — |
| Operating Expense | 244.96 Cr | 191.44 Cr | 105.14 Cr | 87.33 Cr | — |
| Other Operating Expenses | 143.99 Cr | 107.99 Cr | 0.61 Cr | 0.33 Cr | — |
| Depreciation And Amortization In Income Statement | 20.44 Cr | 15.81 Cr | 11.81 Cr | 10.12 Cr | — |
| Depreciation Income Statement | 20.44 Cr | 15.81 Cr | 11.81 Cr | 10.12 Cr | — |
| Gross Profit | 485.31 Cr | 348.60 Cr | 220.46 Cr | 289.49 Cr | — |
| Cost Of Revenue | 211.18 Cr | 221.74 Cr | 230.55 Cr | 229.89 Cr | — |
| Total Revenue | 696.49 Cr | 570.34 Cr | 451.01 Cr | 519.37 Cr | — |
| Operating Revenue | 696.49 Cr | 570.34 Cr | 451.01 Cr | 519.37 Cr | — |
| Interest Income | — | 8.36 Cr | 9.56 Cr | 7.42 Cr | 4.99 Cr |
| Other Special Charges | — | 2.58 Cr | 2.80 Cr | 0.37 Cr | -0.03 Cr |
| Total Other Finance Cost | — | 1.45 Cr | 1.45 Cr | 1.39 Cr | 1.16 Cr |
| Interest Income Non Operating | — | 8.36 Cr | 9.56 Cr | 7.42 Cr | 4.99 Cr |
| Selling General And Administration | — | 46.37 Cr | 43.09 Cr | 36.11 Cr | 33.64 Cr |
| Selling And Marketing Expense | — | 23.18 Cr | 23.87 Cr | 22.38 Cr | 23.12 Cr |
| General And Administrative Expense | — | 23.19 Cr | 19.23 Cr | 13.73 Cr | 10.52 Cr |
| Amortization | — | — | — | 0.39 Cr | 0.39 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Supriya Lifescience Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.